ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /反応

Thioglycolic Acid → rac-4-(1-(4-fluorophenyl)-6-methyl-1H-indazol-5-yl)-1-methyl-3-(pyridin-2-yl)-6,8-dihydro-1H-pyrazolo[3,4-e][1,4]thiazepin-7(4H)-one

HRID 1748820
印刷

反応式

HRID 1748820 の反応式
[CH3:1][N:2]1[C:6]([NH2:7])=[CH:5][C:4]([C:8]2[CH:13]=[CH:12][CH:11]=[CH:10][N:9]=2)=[N:3]1.[F:14][C:15]1[CH:20]=[CH:19][C:18]([N:21]2[C:29]3[C:24](=[CH:25][C:26]([CH:31]=O)=[C:27]([CH3:30])[CH:28]=3)[CH:23]=[N:22]2)=[CH:17][CH:16]=1.[SH:33][CH2:34][C:35](O)=[O:36]>O>[F:14][C:15]1[CH:16]=[CH:17][C:18]([N:21]2[C:29]3[C:24](=[CH:25][C:26]([CH:31]4[S:33][CH2:34][C:35](=[O:36])[NH:7][C:6]5[N:2]([CH3:1])[N:3]=[C:4]([C:8]6[CH:13]=[CH:12][CH:11]=[CH:10][N:9]=6)[C:5]4=5)=[C:27]([CH3:30])[CH:28]=3)[CH:23]=[N:22]2)=[CH:19][CH:20]=1
参加物反応条件実験手順後処理出典と根拠反応ノート

参加物

5

反応物 3

HCID 1133Thioglycolic Acid2 回HCID 133248371-Methyl-3-Pyridin-2-Yl-1H-Pyrazol-5-AmineHCID 867241441-(4-fluorophenyl)-6-methyl-1H-indazole-5-carbaldehyde

生成物 1

HCID 136639940rac-4-(1-(4-fluorophenyl)-6-methyl-1H-indazol-5-yl)-1-methyl-3-(pyridin-2-yl)-6,8-dihydro-1H-pyrazolo[3,4-e][1,4]thiazepin-7(4H)-one収率 30.8%

試薬・触媒・溶媒 1

HCID 962
Water
溶媒

反応条件

温度
110 °C

実験手順

A reaction vial was charged with 1-methyl-3-(pyridin-2-yl)-1H-pyrazol-5-amine (0.07 g, 0.39 mmol, Example #2, step B), 1-(4-fluorophenyl)-6-methyl-1H-indazole-5-carbaldehyde (0.10 g, 0.39 mmol) and water (0.4 mL). The mixture was stirred for about 1 min then 2-mercaptoacetic acid (0.03 mL, 0.39 mmol) was added and the vial was sealed and warmed in a preheated bath to about 110° C. After stirring for 30 min, 2-mercaptoacetic acid (0.014 mL, 0.20 mmol) was added and continued heating for about 90 min. The vial was cooled to ambient temperature and the water was decanted. The solid was sonicated in Et2O (30 mL) and collected by vacuum filtration. The solid was then rinsed with heptane (30 mL) then dissolve in DCM and purified by column chromatography (EtOAc/heptane 100:0 to 0:100) to afford rac-4-(1-(4-fluorophenyl)-6-methyl-1H-indazol-5-yl)-1-methyl-3-(pyridin-2-yl)-6,8-dihydro-1H-pyrazolo[3,4-e][1,4]thiazepin-7(4H)-one (0.06 g, 0.12 mmol, 29%). LC-MS (Table 1, Method g) Rt=2.32 min, m/z 485 (M+H)+. 1H NMR (DMSO-d6, 400 MHz) δ 10.11 (s, 1H), 8.36-8.30 (m, 1H), 8.10 (s, 1H), 7.79-7.69 (m, 3H), 7.64-7.60 (m, 1H), 7.54 (s, 1H), 7.40-7.36 (m, 2H), 7.27 (s, 1H), 7.12-7.04 (m, 1H), 6.74 (s, 1H), 3.90 (s, 3H), 3.42-3.38 (m, 1H), 3.18-3.14 (m, 1H), 2.70 (s, 3H).

後処理

  1. customA reaction
  2. customthe vial was sealed
  3. stirringAfter stirring for 30 min
  4. temperaturecontinued heating for about 90 min
  5. temperatureThe vial was cooled to ambient temperature
  6. customthe water was decanted
  7. customThe solid was sonicated in Et2O (30 mL)
  8. filtrationcollected by vacuum filtration
  9. washThe solid was then rinsed with heptane (30 mL)
  10. dissolutionthen dissolve in DCM
  11. custompurified by column chromatography (EtOAc/heptane 100:0 to 0:100)

出典と根拠

ORDレコード
ord-98eacf46e2744f65855550502acbe3aa
出典データセット
uspto-grants-2015_10
DOI
10.6084/m9.figshare.5104873.v1
特許番号
US09150592B2

反応ノート

このページの内容参加物反応条件実験手順後処理出典と根拠反応ノート